MedTrace Logo

Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1

NCT00033072 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-01-11

No results posted yet for this study

Summary

The purpose of this study is to assess the potential interactions between intravenous methamphetamine and oral selegiline.

Conditions

  • Amphetamine-Related Disorders

Interventions

DRUG

Selegiline

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Thomas Newton, M.D. · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-09-30
Completion
2002-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00033072 on ClinicalTrials.gov